Impact of multiple switching on health care costs and outcomes in generic drug policies

The Hungarian case of losartan

Z. Kaló, Zsolt Abonyi-Tóth, György Rokszin, Tamás Ágh, András Inotai

Research output: Contribution to journalArticle

Abstract

The objective of this study was to estimate the impact of multiple switching of generic antihypertensive therapy on health outcomes and total health expenditure in a retrospective analysis of payer's database. We included patients with hypertension from the National Health Insurance Fund database into our analysis who were treated with losartan or losartan/hydrochlorothiazide (HCT) in 12-month prior to patent expiry of losartan or losartan/HCT. We compared 3-year MACEs (major cardiovascular events, including stroke, myocardial infarct or death) and treatment costs (antihypertensive drugs, other cardiovascular drugs, cardiovascular treatments, non-cardiovascular interventions) from payer's perspective of those patients with multiple switching of generic drug therapy in 12-month after patent expiry (n = 3.280) with those patients who had been switched to a generic losartan or losartan/HCT brand after patent expiry (single switch) without any additional switching in 12-month (N = 3.101). 9.8% of patients with single switch had MACEs over 36-month compared to 10.7% of patients in the multiple switch group (p = 0.247). Compared to baseline year the difference in total annual treatment costs were higher by € 461 in the multiple switch group than in the single switch group (p < 0.001). Further studies are needed to strengthen the evidence on the suboptimal consequences of multiple switching of generic drugs on health outcomes and total treatment costs compared to single switch.

Original languageEnglish
Pages (from-to)1295-1300
Number of pages6
JournalActa Poloniae Pharmaceutica - Drug Research
Volume74
Issue number4
Publication statusPublished - Jan 1 2017

Fingerprint

Generic Drugs
Losartan
Health Care Costs
Antihypertensive Agents
Databases
Cardiovascular Agents
Health
National Health Programs
Health Expenditures
Stroke
Myocardial Infarction
Hypertension
Drug Therapy
Therapeutics
losartan drug combination hydrochlorothiazide

Keywords

  • Adherence
  • Generic drug policy
  • Health outcomes
  • Losartan
  • Price erosion
  • Switching

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Impact of multiple switching on health care costs and outcomes in generic drug policies : The Hungarian case of losartan. / Kaló, Z.; Abonyi-Tóth, Zsolt; Rokszin, György; Ágh, Tamás; Inotai, András.

In: Acta Poloniae Pharmaceutica - Drug Research, Vol. 74, No. 4, 01.01.2017, p. 1295-1300.

Research output: Contribution to journalArticle

Kaló, Z. ; Abonyi-Tóth, Zsolt ; Rokszin, György ; Ágh, Tamás ; Inotai, András. / Impact of multiple switching on health care costs and outcomes in generic drug policies : The Hungarian case of losartan. In: Acta Poloniae Pharmaceutica - Drug Research. 2017 ; Vol. 74, No. 4. pp. 1295-1300.
@article{e9e0433ec27540da9aa5650661296f87,
title = "Impact of multiple switching on health care costs and outcomes in generic drug policies: The Hungarian case of losartan",
abstract = "The objective of this study was to estimate the impact of multiple switching of generic antihypertensive therapy on health outcomes and total health expenditure in a retrospective analysis of payer's database. We included patients with hypertension from the National Health Insurance Fund database into our analysis who were treated with losartan or losartan/hydrochlorothiazide (HCT) in 12-month prior to patent expiry of losartan or losartan/HCT. We compared 3-year MACEs (major cardiovascular events, including stroke, myocardial infarct or death) and treatment costs (antihypertensive drugs, other cardiovascular drugs, cardiovascular treatments, non-cardiovascular interventions) from payer's perspective of those patients with multiple switching of generic drug therapy in 12-month after patent expiry (n = 3.280) with those patients who had been switched to a generic losartan or losartan/HCT brand after patent expiry (single switch) without any additional switching in 12-month (N = 3.101). 9.8{\%} of patients with single switch had MACEs over 36-month compared to 10.7{\%} of patients in the multiple switch group (p = 0.247). Compared to baseline year the difference in total annual treatment costs were higher by € 461 in the multiple switch group than in the single switch group (p < 0.001). Further studies are needed to strengthen the evidence on the suboptimal consequences of multiple switching of generic drugs on health outcomes and total treatment costs compared to single switch.",
keywords = "Adherence, Generic drug policy, Health outcomes, Losartan, Price erosion, Switching",
author = "Z. Kal{\'o} and Zsolt Abonyi-T{\'o}th and Gy{\"o}rgy Rokszin and Tam{\'a}s {\'A}gh and Andr{\'a}s Inotai",
year = "2017",
month = "1",
day = "1",
language = "English",
volume = "74",
pages = "1295--1300",
journal = "Acta Poloniae Pharmaceutica",
issn = "0001-6837",
publisher = "Polish Pharmaceutical Society",
number = "4",

}

TY - JOUR

T1 - Impact of multiple switching on health care costs and outcomes in generic drug policies

T2 - The Hungarian case of losartan

AU - Kaló, Z.

AU - Abonyi-Tóth, Zsolt

AU - Rokszin, György

AU - Ágh, Tamás

AU - Inotai, András

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The objective of this study was to estimate the impact of multiple switching of generic antihypertensive therapy on health outcomes and total health expenditure in a retrospective analysis of payer's database. We included patients with hypertension from the National Health Insurance Fund database into our analysis who were treated with losartan or losartan/hydrochlorothiazide (HCT) in 12-month prior to patent expiry of losartan or losartan/HCT. We compared 3-year MACEs (major cardiovascular events, including stroke, myocardial infarct or death) and treatment costs (antihypertensive drugs, other cardiovascular drugs, cardiovascular treatments, non-cardiovascular interventions) from payer's perspective of those patients with multiple switching of generic drug therapy in 12-month after patent expiry (n = 3.280) with those patients who had been switched to a generic losartan or losartan/HCT brand after patent expiry (single switch) without any additional switching in 12-month (N = 3.101). 9.8% of patients with single switch had MACEs over 36-month compared to 10.7% of patients in the multiple switch group (p = 0.247). Compared to baseline year the difference in total annual treatment costs were higher by € 461 in the multiple switch group than in the single switch group (p < 0.001). Further studies are needed to strengthen the evidence on the suboptimal consequences of multiple switching of generic drugs on health outcomes and total treatment costs compared to single switch.

AB - The objective of this study was to estimate the impact of multiple switching of generic antihypertensive therapy on health outcomes and total health expenditure in a retrospective analysis of payer's database. We included patients with hypertension from the National Health Insurance Fund database into our analysis who were treated with losartan or losartan/hydrochlorothiazide (HCT) in 12-month prior to patent expiry of losartan or losartan/HCT. We compared 3-year MACEs (major cardiovascular events, including stroke, myocardial infarct or death) and treatment costs (antihypertensive drugs, other cardiovascular drugs, cardiovascular treatments, non-cardiovascular interventions) from payer's perspective of those patients with multiple switching of generic drug therapy in 12-month after patent expiry (n = 3.280) with those patients who had been switched to a generic losartan or losartan/HCT brand after patent expiry (single switch) without any additional switching in 12-month (N = 3.101). 9.8% of patients with single switch had MACEs over 36-month compared to 10.7% of patients in the multiple switch group (p = 0.247). Compared to baseline year the difference in total annual treatment costs were higher by € 461 in the multiple switch group than in the single switch group (p < 0.001). Further studies are needed to strengthen the evidence on the suboptimal consequences of multiple switching of generic drugs on health outcomes and total treatment costs compared to single switch.

KW - Adherence

KW - Generic drug policy

KW - Health outcomes

KW - Losartan

KW - Price erosion

KW - Switching

UR - http://www.scopus.com/inward/record.url?scp=85025446123&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025446123&partnerID=8YFLogxK

M3 - Article

VL - 74

SP - 1295

EP - 1300

JO - Acta Poloniae Pharmaceutica

JF - Acta Poloniae Pharmaceutica

SN - 0001-6837

IS - 4

ER -